Panelist discusses how the development of nanoliposomal irinotecan led to the NAPOLI-1 trial showing a survival benefit in second-line treatment and subsequently the NAPOLI-3 trial demonstrating the superiority of NALIRIFOX (liposomal irinotecan, 5-fluorouracil [5-FU], leucovorin, oxaliplatin) over gemcitabine/nab-paclitaxel in first-line metastatic disease.
Overview of Clinical Trial Data A panelist discusses how first-line treatment recommendations are based on 3 pivotal phase 3 randomized trials: PRODIGE 4 (which established FOLFIRINOX superiority over gemcitabine with 11.1 vs 6.8 months overall survival despite higher toxicity), MPACT (showing gemcitabine plus nab-paclitaxel benefit over single-agent gemcitabine with 8.5 vs 6.7 months survival), and the recent NAPOLI-3 (demonstrating NALIRIFOX superiority over gemcitabine plus nab-paclitaxel with 11.1 vs 9.2 months overall survival in over 750 patients across 180 sites).
A panelist discusses how treatment selection for metastatic pancreatic adenocarcinoma involves evaluating multiple factors including genetic and somatic mutations (particularly homologous recombination deficiency [HRD] alterations like BRCA1/2 and PALB2, which favor platinum-based regimens), patient age and performance status, liver function status, and drug metabolism genotype testing such as dihydropyrimidine dehydrogenase (DPD) deficiency screening to avoid severe 5-FU toxicity in rare cases of homozygous variants.
Panelist discusses how the landmark ACCORD 11 trial established FOLFIRINOX (leucovorin calcium, fluorouracil, irinotecan hydrochloride, and oxaliplatin) as superior to gemcitabine for fit, young patients, whereas the MPACT trial demonstrated that gemcitabine plus nab-paclitaxel provided a more tolerable option for older patients with less preserved performance status.
Panelist discusses how CA 19-9 serves as a useful tumor marker for disease monitoring and recurrence detection in patients with pancreatic cancer, though it requires normalization of bilirubin levels for accurate baseline assessment.
A panelist discusses how first-line treatment for metastatic pancreatic cancer depends on performance status. ECOG 0-1 patients receive preferred options like FOLFIRINOX, modified FOLFIRINOX, or the newly FDA-approved NALIRIFOX regimen (which includes liposomal irinotecan for enhanced drug delivery), whereas ECOG 2 patients typically receive gemcitabine plus nab-paclitaxel, and ECOG 3 patients receive palliative care.
A panelist discusses how a man aged 82 years with good performance status presented with unexplained weight loss and abdominal pain, leading to a diagnosis of metastatic pancreatic adenocarcinoma with KRAS G12D and TP53 mutations confirmed through imaging, biopsy, and next-generation sequencing (NGS) testing.
Panelist discusses how genetic testing is recommended for all patients with pancreatic adenocarcinoma at diagnosis, including both germline testing for hereditary cancer syndromes and tumor profiling using next-generation sequencing (NGS) assays to identify actionable mutations.
Panelist discusses how pancreatic adenocarcinoma remains one of the deadliest cancers with poor survival rates, presenting a case of a 58-year-old patient with locally advanced disease and reviewing National Comprehensive Cancer Network treatment guidelines that mirror metastatic disease approaches.
An expert discusses the evolving landscape of large B-cell lymphoma (LBCL) treatment, highlighting emerging CAR T-cell targets and bispecific antibody strategies, the potential shift toward more personalized, less toxic therapies, and the ongoing challenges of improving patient access, referral, and posttreatment management to maximize outcomes.
An expert discusses the emerging role of bispecific antibodies in lymphoma treatment, highlighting their expanding use across treatment lines—including as alternatives or bridges to CAR T-cell therapy—their promising efficacy, more manageable toxicity profiles, and potential to improve patient quality of life through flexible care models.
An expert discusses the advances in managing CAR T-cell therapy toxicities, emphasizing aggressive early treatment of acute complications, the importance of coordinated long-term monitoring with community providers, and how real-world data validate the therapy’s safety and effectiveness across diverse patient populations.
An expert highlights how optimizing CAR T-cell therapy requires simplifying the treatment process, reducing insurance delays, addressing that 40% to 50% of patients may need further therapy, managing long-term immune and safety concerns, investigating risks like second malignancies, and enhancing collaboration between treatment centers and local providers to improve patient experience and outcomes.
An expert explains that T-cell fitness is critical for CAR T-cell therapy success, as earlier use—before multiple rounds of chemotherapy or bispecific antibody exposure—helps preserve T-cell quality and function, thereby improving response rates and long-term outcomes; consequently, early referral for CAR T is recommended to optimize treatment effectiveness.
An expert discusses that while CAR T-cell therapies carry risks such as cytokine release syndrome and neurotoxicity, advancements in supportive care and monitoring have significantly improved their safety profiles—allowing clinicians to tailor product selection, such as favoring axi-cel for rapidly progressing disease due to its survival benefit and quick manufacturing, or liso-cel for more frail patients requiring lower toxicity exposure.
An expert discusses the complexities of sequencing antibody-drug conjugates (ADCs) in metastatic triple-negative breast cancer, emphasizing the need for biomarker-driven treatment personalization and crossover trial designs to optimize early use and improve patient outcomes.
An expert discusses the selection of CAR T-cell therapies for third-line large B-cell lymphoma (LBCL), noting that while all approved products show comparable efficacy, differences in co-stimulatory domains, toxicity profiles, manufacturing timelines, and patient-specific factors guide individualized treatment decisions.
An expert discusses the transformative impact of CAR T-cell therapy in relapsed/refractory large B-cell lymphoma, highlighting long-term data that support durable remission—and potential cure—for a subset of patients, while emphasizing its favorable long-term safety profile and growing role in the evolving standard of care.
Panelists discuss how future research priorities include developing predictive biomarkers, exploring quadruple therapy combinations, determining optimal checkpoint inhibitor duration and sequencing strategies, incorporating immunotherapy into earlier treatment lines with chemoradiation, and utilizing circulating tumor DNA for prognostic monitoring after definitive therapy.
An expert discusses that while the liso-cel trial did not show a statistically significant overall survival benefit—likely due to its small sample size and crossover design—it still demonstrated durable responses with a favorable safety profile, offering a valuable, lower-toxicity CAR T option for patients with relapsed or refractory large B-cell lymphoma, particularly those less suited for more aggressive therapies like axi-cel.
An expert discusses how the ZUMA-7 trial marked a pivotal shift in the treatment of primary refractory diffuse large B-cell lymphoma by demonstrating that second-line CAR T-cell therapy not only improves overall survival compared with standard care but also leads to faster functional recovery, reinforcing the importance of early referral and positioning CAR T as a preferred curative-intent option rather than a last resort.
Panelists discuss how future directions in chronic lymphocytic leukemia (CLL) treatment include promising developments with Bruton tyrosine kinase (BTK) degraders, noncovalent BTK inhibitors, alternative BCL2 inhibitors like sonrotoclax, bispecific antibodies for consolidation strategies, and addressing remaining gaps such as Richter transformation risk, infection susceptibility, and secondary malignancy surveillance in this rapidly evolving therapeutic landscape.
Panelists discuss how real-world evidence studies from databases like Flatiron demonstrate that second-generation Bruton tyrosine kinase (BTK) inhibitors perform better than first-generation agents in clinical practice, providing hypothesis-generating data that support clinical observations about treatment tolerability and infection rates, although these retrospective analyses should complement rather than replace randomized controlled trial evidence.
Panelists discuss how emerging combination strategies like acalabrutinib-venetoclax (AMPLIFY) and zanubrutinib-venetoclax (SEQUOIA Arm D) are expanding time-limited treatment options beyond the traditional venetoclax-obinutuzumab approach. However, they emphasize the need for longer follow-up data before widespread adoption and careful patient selection based on individual preferences and risk profiles.
Panelists discuss how to effectively mitigate Bruton tyrosine kinase (BTK) inhibitor toxicities through careful patient risk stratification, collaboration with cardio-oncologists, routine monitoring for arrhythmias and hypertension, appropriate use of dose reductions and drug holidays for chronic toxicities, and consideration of time-limited strategies to reduce long-term adverse effect exposure while maintaining treatment efficacy.
Panelists discuss how measurable residual disease (MRD) testing should be used primarily for prognostic information rather than routine treatment decision-making, with current guidelines recommending against using MRD results to alter therapy duration or change treatments. They question whether MRD negativity represents a sufficient surrogate end point for drug approvals, given the lack of cure potential and variable kinetics of MRD conversion.
Panelists discuss how obinutuzumab combinations with acalabrutinib (ELEVATE-TN data) and venetoclax (CLL14 data) provide compelling treatment options. The former shows continued progression-free survival benefits and curve separation over time, whereas the latter offers outstanding fixed-duration results even for high-risk patients. Both require careful consideration of intravenous (IV) vs oral preferences and long-term safety profiles.
Panelists discuss how the updated SEQUOIA Arm C data demonstrate that zanubrutinib monotherapy achieves a remarkable 72% progression-free survival at 5 years for high-risk patients with deletion 17p, showing similar outcomes to TP53 wild-type patients and establishing continuous monotherapy as an excellent option for these highest-risk patients.
Panelists discuss how to select among available Bruton tyrosine kinase (BTK) inhibitor treatment regimens for continuous vs fixed-duration strategies. They weigh the benefits of oral-only regimens against combination therapies that include intravenous (IV) infusions, while acknowledging the limited retreatment data for newer oral doublets.
Panelists discuss how the treatment landscape for treatment-naive patients with chronic lymphocytic leukemia (CLL) is rapidly evolving with new guideline updates every 6 to 12 months. They categorize approaches into fixed-duration vs continuous treatment strategies while emphasizing the need to study different molecular subtypes of CLL separately in future clinical trials.